[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1120397T1 - Amino αμιδια τυπου δενδριμερους που εχουν δραστικοτητα αναστολεα διαυλου νατριου για τη θεραπεια ξηρου οφθαλμου και αλλων βλεννογονικων ασθενειων - Google Patents

Amino αμιδια τυπου δενδριμερους που εχουν δραστικοτητα αναστολεα διαυλου νατριου για τη θεραπεια ξηρου οφθαλμου και αλλων βλεννογονικων ασθενειων

Info

Publication number
CY1120397T1
CY1120397T1 CY20181100713T CY181100713T CY1120397T1 CY 1120397 T1 CY1120397 T1 CY 1120397T1 CY 20181100713 T CY20181100713 T CY 20181100713T CY 181100713 T CY181100713 T CY 181100713T CY 1120397 T1 CY1120397 T1 CY 1120397T1
Authority
CY
Cyprus
Prior art keywords
sodium channel
treatment
denmarket
amidia
amino
Prior art date
Application number
CY20181100713T
Other languages
English (en)
Inventor
Michael Ross Johnson
William Robert Thelin
Richard C. Boucher
Original Assignee
Parion Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences, Inc. filed Critical Parion Sciences, Inc.
Publication of CY1120397T1 publication Critical patent/CY1120397T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32—(Amino-pyrazinoyl) guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/34—(Amino-pyrazine carbonamido) guanidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχονται αναστολείς διαύλου νατρίου που αντιπροσωπεύονται από τον τύπο (I) όπου οι συντακτικές μεταβλητές ορίζονται στο παρόν. Η εφεύρεση επίσης περιλαμβάνει ποικιλία συνθέσεων, συνδυασμών και μεθόδων θεραπείας χρησιμοποιώντας αυτούς τους αναστολείς διαύλου νατρίου της εφεύρεσης.
CY20181100713T 2012-05-29 2018-07-06 Amino αμιδια τυπου δενδριμερους που εχουν δραστικοτητα αναστολεα διαυλου νατριου για τη θεραπεια ξηρου οφθαλμου και αλλων βλεννογονικων ασθενειων CY1120397T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261652481P 2012-05-29 2012-05-29
PCT/US2013/043080 WO2013181232A2 (en) 2012-05-29 2013-05-29 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

Publications (1)

Publication Number Publication Date
CY1120397T1 true CY1120397T1 (el) 2019-07-10

Family

ID=49671001

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100713T CY1120397T1 (el) 2012-05-29 2018-07-06 Amino αμιδια τυπου δενδριμερους που εχουν δραστικοτητα αναστολεα διαυλου νατριου για τη θεραπεια ξηρου οφθαλμου και αλλων βλεννογονικων ασθενειων

Country Status (24)

Country Link
US (4) US8980898B2 (el)
EP (2) EP3366680B1 (el)
JP (3) JP6272312B2 (el)
KR (1) KR102109223B1 (el)
CN (1) CN104334535B (el)
AU (2) AU2013267504B2 (el)
BR (1) BR112014029329A2 (el)
CA (1) CA2872029A1 (el)
CY (1) CY1120397T1 (el)
DK (1) DK2855435T3 (el)
EA (2) EA201990616A3 (el)
ES (1) ES2675588T3 (el)
HK (1) HK1204276A1 (el)
HU (1) HUE039734T2 (el)
LT (1) LT2855435T (el)
MX (1) MX2014014648A (el)
MY (1) MY171122A (el)
PH (1) PH12014502624A1 (el)
PL (1) PL2855435T3 (el)
PT (1) PT2855435T (el)
SG (1) SG11201407867VA (el)
SI (1) SI2855435T1 (el)
TR (1) TR201809148T4 (el)
WO (1) WO2013181232A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide having strong sodium channel blocking activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
ES2619954T3 (es) 2012-12-17 2017-06-27 Parion Sciences, Inc. Derivados de cloropiracinocarboxamida útiles para el tratamiento de enfermedades favorecidas por una hidratación mucosa insuficiente
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
CA2922162A1 (en) 2013-08-23 2015-02-26 Parion Sciences, Inc. Dithiol mucolytic agents
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
SG11201705790SA (en) 2015-01-30 2017-08-30 Parion Sciences Inc Novel monothiol mucolytic agents
WO2016133967A2 (en) * 2015-02-18 2016-08-25 Parion Sciences, Inc. Sodium channel blockers for skin disorders
CN107708680A (zh) 2015-04-30 2018-02-16 帕里昂科学公司 新的二硫醇粘液溶解剂的前药
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
CN109752354A (zh) * 2017-11-06 2019-05-14 锐准医光股份有限公司 整合米洛光学干涉显微术与荧光显微术的光学切层装置
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CN109160888B (zh) * 2018-10-09 2022-03-01 四川医立特生物医药有限公司 一种含脒基的对称化合物及其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (el) 1962-10-30
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US4312860A (en) 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
US4479932A (en) 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5100806A (en) 1989-03-24 1992-03-31 Macri James N Method for detecting Edwards syndrome
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
CA2063273C (en) 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
CA2444415A1 (en) 1991-07-02 1993-01-21 Nektar Therapeutics Method and device for delivering aerosolized medicaments
ES2216800T3 (es) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
EP1769819A3 (en) 1995-04-14 2013-05-22 GlaxoSmithKline LLC Metered dose inhaler for fluticasone propionate
KR100606131B1 (ko) 1997-02-06 2006-07-31 인스파이어 파마슈티컬스 인코퍼레이티드 디뉴클레오티드 및 그의 용도
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
WO2000023023A1 (en) 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6329034B1 (en) 1999-01-18 2001-12-11 Roger L. Pendry Label having tab member and methods for forming, applying and using the same
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
ATE294608T1 (de) 1999-06-05 2005-05-15 Innovata Biomed Ltd Verabreichungsystem für medikamente
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
WO2001026720A1 (en) 1999-10-12 2001-04-19 Shl Medical Ab Inhaler
IL149085A0 (en) 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
GB9928265D0 (en) 1999-12-01 2000-01-26 Innovata Biomed Ltd Inhaler
SE9904706D0 (sv) 1999-12-21 1999-12-21 Astra Ab An inhalation device
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
FR2813593B1 (fr) 2000-09-07 2002-12-06 Valois Sa Dispositif de distribution de produit fluide de type multidose
GB0026647D0 (en) 2000-10-31 2000-12-13 Glaxo Group Ltd Medicament dispenser
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
EP1542667B1 (en) 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
HUE059464T2 (hu) 2003-04-11 2022-11-28 Ptc Therapeutics Inc 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
EP1670475A4 (en) 2003-08-18 2009-04-15 Parion Sciences Inc ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
KR20060037450A (ko) 2003-08-18 2006-05-03 패리온 사이언스 인코퍼레이티드 사이클릭 피라지노일구아니딘 나트륨 채널 차단제
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7499570B2 (en) 2004-03-02 2009-03-03 Siemens Corporate Research, Inc. Illumination invariant change detection
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US8143256B2 (en) 2004-08-18 2012-03-27 Parion Sciences, Inc. Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
JP2008510702A (ja) * 2004-08-18 2008-04-10 マイケル・アール・ジョンソン 脂肪族アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬
JP2008515985A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制の化合物とその使用方法
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
ATE551421T1 (de) 2005-01-07 2012-04-15 Alnylam Pharmaceuticals Inc Rnai modulation von rsv und deren therapeutische verwendungen
US7588817B2 (en) 2005-03-11 2009-09-15 Jds Uniphase Corporation Engraved optically variable image device
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
WO2007065437A2 (en) 2005-12-06 2007-06-14 P2-Science Aps Modulation of the p2y2 receptor pathway
EP1974212A1 (en) 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
KR20150001844A (ko) 2006-01-24 2015-01-06 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
TWI334164B (en) 2006-06-07 2010-12-01 Ind Tech Res Inst Method of manufacturing nitride semiconductor substrate and composite material substrate
WO2007146867A2 (en) * 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
CA2653773A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
SI2035004T1 (sl) 2006-06-09 2012-12-31 Parion Sciences, Inc. S fenilom substituirani pirazinoilgvanidinski blokatorji natrijevih kanalov, ki imajo beta-agonistiäśno aktivnost
CN101534813A (zh) * 2006-09-07 2009-09-16 帕里昂科学公司 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
JP2010502739A (ja) 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善
JP2010502738A (ja) 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8288391B2 (en) * 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
WO2008124496A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
EP2152316A4 (en) 2007-04-26 2011-03-23 Quark Pharmaceuticals Inc THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
DK2011907T3 (da) 2007-07-02 2010-05-17 Centre Nat Rech Scient Fremgangsmåde til fremstilling af hydrogengas og carbon-nanorør ud fra en katalytisk nedbrydning af ethanol
US8131579B2 (en) 2007-07-09 2012-03-06 Raytheon Company Web-based system and application for collaborative planning of a networked program schedule
CN103784408A (zh) 2007-07-24 2014-05-14 安迅生物制药公司 用于制备微粒的技术
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009061368A1 (en) 2007-11-06 2009-05-14 Benaroya Research Institute Inhibition of versican with sirna and other molecules
US8124607B2 (en) * 2008-02-26 2012-02-28 Parion Sciences, Inc. Poly aromatic pyrazinoylguanidine sodium channel blockers
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
NZ588006A (en) 2008-03-31 2012-08-31 Vertex Pharma Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
AU2009308241B2 (en) 2008-10-23 2016-01-07 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US20100316628A1 (en) 2008-12-09 2010-12-16 The General Hospital Corporation Agents and methods for treating respiratory disorders
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide having strong sodium channel blocking activity
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
ES2619954T3 (es) 2012-12-17 2017-06-27 Parion Sciences, Inc. Derivados de cloropiracinocarboxamida útiles para el tratamiento de enfermedades favorecidas por una hidratación mucosa insuficiente
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида

Also Published As

Publication number Publication date
EA032734B1 (ru) 2019-07-31
EP2855435B1 (en) 2018-04-11
US20150099764A1 (en) 2015-04-09
HUE039734T2 (hu) 2019-01-28
EA201990616A2 (ru) 2019-07-31
AU2013267504B2 (en) 2017-11-02
US9878988B2 (en) 2018-01-30
EP3366680A1 (en) 2018-08-29
EP2855435A4 (en) 2015-12-09
WO2013181232A2 (en) 2013-12-05
SG11201407867VA (en) 2014-12-30
EA201491816A1 (ru) 2015-04-30
US10526292B2 (en) 2020-01-07
TR201809148T4 (tr) 2018-07-23
AU2018200363B2 (en) 2019-10-17
US20160122306A1 (en) 2016-05-05
JP6272312B2 (ja) 2018-01-31
HK1204276A1 (en) 2015-11-13
ES2675588T3 (es) 2018-07-11
KR20150023302A (ko) 2015-03-05
MX2014014648A (es) 2015-09-04
EP3366680B1 (en) 2020-05-13
JP2020059732A (ja) 2020-04-16
JP2018058897A (ja) 2018-04-12
KR102109223B1 (ko) 2020-05-11
LT2855435T (lt) 2018-09-10
BR112014029329A2 (pt) 2017-06-27
AU2013267504A1 (en) 2014-11-06
MY171122A (en) 2019-09-26
PH12014502624B1 (en) 2015-01-26
AU2018200363A1 (en) 2018-02-08
US9260398B2 (en) 2016-02-16
CN104334535A (zh) 2015-02-04
US20180111907A1 (en) 2018-04-26
PL2855435T3 (pl) 2018-10-31
US20130324559A1 (en) 2013-12-05
PH12014502624A1 (en) 2015-01-26
DK2855435T3 (en) 2018-07-16
JP2015518050A (ja) 2015-06-25
PT2855435T (pt) 2018-07-03
CN104334535B (zh) 2016-10-05
EA201990616A3 (ru) 2019-12-30
CA2872029A1 (en) 2013-12-05
US8980898B2 (en) 2015-03-17
WO2013181232A3 (en) 2014-01-23
EP2855435A2 (en) 2015-04-08
SI2855435T1 (sl) 2018-09-28

Similar Documents

Publication Publication Date Title
CY1120397T1 (el) Amino αμιδια τυπου δενδριμερους που εχουν δραστικοτητα αναστολεα διαυλου νατριου για τη θεραπεια ξηρου οφθαλμου και αλλων βλεννογονικων ασθενειων
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
CY1122918T1 (el) Προφαρμακα ενωσης αναστολεα jak για την θεραπεια μιας γαστρεντερικης φλεγμονωδους νοσου
CY1123487T1 (el) Διαμορφωτες του ρυθμιστη αγωγιμοτητας διαμεμβρανης κυστικης ινωσης
CY1120273T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση φαρνεσοειδων υποδοχεων χ
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
CY1119620T1 (el) Αναστολεις νεπριλυσινης
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
CY1120080T1 (el) Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2020004504A (es) Derivados de fenoximetilo.
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201792471A1 (ru) Бигетероарильные соединения и их применения
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
EA201590321A1 (ru) Дейтерированный барицитиниб
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac